VC
APGE icon

Vivo Capital’s Apogee Therapeutics APGE Stock Holding History

Vivo Capital’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-400,000
Closed -$11.2M – 43
2023
Q4 		$11.2M Hold
400,000
– – 0.92% 23
2023
Q3 		$8.52M Buy
+400,000
New +$8.81M 0.93% 27

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Vivo Capital's APGE Position: Q1 2024 in Review

Vivo Capital sold out of Apogee Therapeutics (APGE) in Q1 2024, closing a stake of 400,000 shares — an estimated $11.2M sold.

Vivo Capital first reported a position in APGE in Q3 2023 and held it in 2 quarters. The position peaked at $11.2M in Q4 2023. 139 funds tracked by Wall St. Rank hold APGE as of Q1 2024.

  • Vivo Capital reported no remaining Apogee Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Vivo Capital sold 400,000 Apogee Therapeutics shares in Q1 2024, an estimated $11.2M.
  • Vivo Capital first reported a position in Apogee Therapeutics in Q3 2023 and held it in 2 quarters.
  • Vivo Capital's Apogee Therapeutics position peaked at $11.2M in Q4 2023.
  • 139 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q1 2024.

Based on Vivo Capital's 13F filing for Q1 2024, filed 22 Apr 2024.